Table 2.

Correlation between antibody dosage patent and approved dosage of gemtuzumab ozogamicin. The patent is broader than the approved dosage, hence anticipating later factionated dosages that could have given rise to new patent protection.

Approved antibody	Patent	Priority date	Claimed dosage	Dosage in the FDA label
Gemtuzumab ozogamicin	US7727968B2 (wihdrawn by patentee)	Nov. 6, 2002	Method of treating AML consisting essentially of: (a) administering a first course (…) of (…)about 3 to 9 mg/m2 gemtuzumab ozogamicin for one day (plus chemotherapy) (b) administering a second course of (…) of about 3 to 9 mg/m2 gemtuzumab ozogamicin for one day (plus chemotherapy) (…) and (c) administering a third course (chemotherapy)	9 mg/m2, infused over a 2-hour period. The recommended treatment course with Mylotarg is a total of 2 doses with 14 d between the doses